Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

282 results about "Triacylglycerol VLDL" patented technology

Novel elongase gene and method for producing multiple-unsaturated fatty acids

The invention relates to a novel elongase gene with the sequences stated in sequence SEQ ID NO:1, SEQ ID NO: 3, SEQ ID NO: 5 and SEQ ID NO: 7 or their homologs, derivatives or analogs, to a gene construct comprising this gene or its homologs, derivatives and analogs, and to its use. The invention also relates to vectors or transgenic organisms comprising an elongase gene with the sequence SEQ ID NO:1, SEQ ID NO: 3, SEQ ID NO: 5 and SEQ ID NO: 7 or its homologs, derivatives and analogs. The invention furthermore relates to the use of the elongase gene sequences alone or in combination with further elongases and / or further fatty acid biosynthesis genes. The present invention relates to a novel elongase gene with the sequence SEQ ID NO:1 or its homologs, derivatives and analogs. Furthermore, the invention relates to a process for the preparation of polyunsaturated fatty acids and to a process for introducing DNA into organisms which produce large amounts of oils and, in particular, oils with a high content of unsaturated fatty acids. Moreover, the invention relates to an oil and / or a fatty acid preparation with a higher content of polyunsaturated fatty acids with at least two double bonds and / or a triacylglycerol preparation with a higher content of polyunsaturated fatty acids with at least two double bonds.
Owner:BASF AG

Process to remove impurities from triacylglycerol oil

The present invention is directed to a process to remove impurities from triacylglycerol oil including mixing the oil and a fluidic agent, pumping the mixture through a flow-through hydrodynamic cavitation apparatus at a pre-determined inlet pump pressure, creating hydrodynamic cavitation in the mixture, maintaining the hydrodynamic cavitation for a pre-determined period of time, moving the impurities from the oil to the fluidic agent, and then separating the fluidic agent from the oil. The impurities can include phytosterols, sterol glucosides, acylated sterol glucosides, in which case the fluidic agent is water, an alkali hydroxide, an inorganic base, an organic base, phosphoric acid, citric acid, acetic acid or a mixture thereof. The impurities may also include phosphatides, in which case and the fluidic agent comprises water and an enzyme such as phospholipase, a lipid acyltransferase or a mixture thereof.
Owner:CAVITATION TECH

Novel elongase gene, and process for the preparation of polyunsaturated fatty acids

The invention relates to a novel elongase gene with the sequences stated in sequence SEQ ID NO:1, SEQ ID NO: 3, SEQ ID NO: 5 and SEQ ID NO: 7 or their homologs, derivatives or analogs, to a gene construct comprising this gene or its homologs, derivatives and analogs, and to its use. The invention also relates to vectors or transgenic organisms comprising an elongase gene with the sequence SEQ ID NO:1, SEQ ID NO: 3, SEQ ID NO: 5 and SEQ ID NO: 7 or its homologs, derivatives and analogs. The invention furthermore relates to the use of the elongase gene sequences alone or in combination with further elongases and / or further fatty acid biosynthesis genes. The present invention relates to a novel elongase gene with the sequence SEQ ID NO:1 or its homologs, derivatives and analogs.Furthermore, the invention relates to a process for the preparation of polyunsaturated fatty acids and to a process for introducing DNA into organisms which produce large amounts of oils and, in particular, oils with a high content of unsaturated fatty acids. Moreover, the invention relates to an oil and / or a fatty acid preparation with a higher content of polyunsaturated fatty acids with at least two double bonds and / or a triacylglycerol preparation with a higher content of polyunsaturated fatty acids with at least two double bonds.
Owner:BASF AG

Lauric fat based structuring agents to reduce saturated fat

The present invention relates to a lipid composition comprising at least 5 wt % of a structuring agent dispersed in oil or fat wherein the structuring agent comprises at least 50 wt % of triacylglycerol containing a glycerin skeleton esterified with one type of saturated fatty acid having a chain length of either 10:0, 12:0 or 14:0. Further aspects of the invention are: the structuring agent, a food product comprising the lipid composition, the use of the lipid composition as a structure stabilizer or a moisture barrier in a food product; and a method for preparing the lipid composition.
Owner:NESTEC SA

Diacylglycerol acyl transferase proteins

InactiveUS7135617B2Increase percentageIncreased DAGAT activitySugar derivativesPeptide/protein ingredientsDiseaseMortierella ramanniana
The invention provides diacylglycerol acyltransferase (DAGAT) proteins, wherein said proteins are active in the formation of triacylglycerol from fatty acyl and diacylglycerol substrates. In one aspect, Mortierella ramanniana DAGAT proteins have been isolated and have molecular weights of between approximately 36 and 37 kDa as measured by SDS-PAGE. The invention also provides novel DAGAT polynucleotide and polypeptide sequences and to methods of producing such polypeptides using recombinannt techniques. In addition, methods are provided for using such sequences to alter triacylglycerol levels in plants and to treat diseases associated with altered DAGAT activity or expression.
Owner:MONSANTO TECH LLC

Diacylglycerol acyl transferase proteins

InactiveUS7741532B2BacteriaPeptide/protein ingredientsMortierella ramannianaPolynucleotide
The invention provides diacylglycerol acyltransferase (DAGAT) proteins, wherein said proteins are active in the formation of triacylglycerol from fatty acyl and diacylglycerol substrates. In one aspect, Mortierella ramanniana DAGAT proteins have been isolated and have molecular weights of between approximately 36 and 37 kDa as measured by SDS-PAGE. The invention also provides novel DAGAT polynucleotide and polypeptide sequences and to methods of producing such polypeptides using recombinant techniques. In addition, methods are provided for using such sequences to alter triacylglycerol levels in plants and to treat diseases associated with altered DAGAT activity or expression.
Owner:MONSANTO TECH LLC

Fractionation of phytosterol esters in oil

A composition of at least one diacylglycerol and at least one phytosterol and / or phytostanol ester dissolved or dispersed in an edible oil and / or edible fat, and further optionally containing monoglycerides. Phytosterol esters may be beta-sitosterol, campesterol, stigmasterol and brassicasterol esters. Phytostanol esters may be stigmasterol, campestanol and sitostanol. The phytosterol and / or phytostanol esters are preferably esters of C14-C22, preferably C16-C18 saturated or unsaturated fatty acids, particularly oleic, linoleic, linolenic, palmitic and stearic acids. The diacylglycerol(s) are preferably 1,3-di-fatty acyl glycerol(s). A process for preparing compositions enriched with triacylglycerol(s) and phytosterol and / or phytostanol esters of mainly unsaturated fatty acid(s) or of mainly saturated fatty acid(s). Dietary food supplements and alimentary products derived from the above compositions.
Owner:ENZYMOTEC

Omega-3 fatty acids in the treatment of depression

InactiveUS6852870B2Reduce and eliminate its symptomReduce severityBiocideNervous disorderGlycerolCholine Phosphate
The present invention is directed to a method of treating patients with major depression by administering omega-3 fatty acids. These may be administered in a substantially purified form, as part of a pharmaceutical composition, or as part of a larger molecule, e.g., a triacylglycerol, which releases free fatty acid after ingestion by a patient.The present invention is also directed to triacylglycerols which are esterified at the gamma cardon of glycerol to phosphocholine and at either the alpha or beta carbon of glycerol to an omega-3 fatty acid. These “omega-3 phoshatidylcholines” are also used in the treatment of patients with major depression.
Owner:STOLL ANDREW
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products